Clinical Trial: PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07611214) titled 'PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis' on May 13.

Brief Summary: The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS(R) in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).

Study Start Date: April 22

Study Type: INTERVENTIONAL

Condition: Lupus Nephritis

Intervention: DRUG: LUPKYNIS

voclosporin

BIOLOGICAL: belimumab, obinutuzumab or anifrolumab

BENLYSTA (belimumab), GAZYVA (obinutuzumab) or SAPHNELO (anifrolumab)

DRUG: mycophenolic acid analog (MPA...